Lymphoma Clinical Trials in Nashville

Showing 21-40 of 629 trials

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

NCT06150664

This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 cohorts: Dose Escalation and Dose Expansion.

Non Small Cell Lung CancerTriple Negative Breast CancerHodgkin Lymphoma+2 more

Compass Therapeutics85 participantsStarted Mar 2024

Margate, Florida, United States • Orlando, Florida, United States • Sarasota, Florida, United States +6 more locations

Not Yet RecruitingPhase 1< 1 mile

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

NCT07226843

The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers. For each participant, the study could last about 9 months or possibly longer including screening.

Lymphoma, Non-Hodgkin'sLymphoma, Diffuse Large B-CellFollicular Lymphoma

Eli Lilly and Company360 participantsStarted Apr 2026

Scottsdale, Arizona, United States • Duarte, California, United States • Los Angeles, California, United States +42 more locations

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

Lymphoma Trials in Other Cities

Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma

DS-3201b in Participants With Lymphomas

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma

A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

Assessment of Cognitive Function in Breast Cancer and Lymphoma Patients Receiving Chemotherapy

A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Other Conditions in Nashville